S-1: Advanced Biomed Files S-1 for $25M Equity Line Resale, Faces Nasdaq Delisting Threat Amidst Continued Losses

Advanced Biomed Inc., a pre-revenue biotechnology company, filed an S-1 registration statement for the resale of up to 40 million shares by a selling stockholder under a $25 million equity line of credit, while grappling with persistent net losses and a Nasdaq minimum bid price deficiency.

Summary

• Advanced Biomed Inc. is a Nevada-incorporated holding company focused on integrating semiconductor and biotechnology for early cancer detection, operating primarily through subsidiaries in Taiwan and Hong Kong, with a Shanghai subsidiary for clinical trials in Mainland China.
• The company has developed several devices (A+Pre, AC-1000, A+CellScan, A+SCDrop) and four immunostaining kits, with A+Pre and AC-1000 and their chips already cleared by China's NMPA.
• A+LCGuard, a Class III medical device for early lung cancer screening, completed R&D between August 2020 and September 2022, and clinical research is planned to begin by the end of October 2025, with completion anticipated within six months.
• Pre-mass production trials for A+Pre Chips and AC-1000 Enrichment Chips showed promising results, with average tumor cell recovery rates of 94% (target 90%) for A+Pre and 79.5% (target 75%) for AC-1000, and blood cell depletion rates exceeding targets.
• The global liquid biopsy market was valued at $8,937.68 million in 2022 and is projected to grow to $22,865.56 million by 2030, at a CAGR of 12.46%.
• The company has not commenced product sales or generated revenue, and expects to incur continuous losses for the next two to three years.
• Advanced Biomed received a Nasdaq Deficiency Notice on July 18, 2025, for its common stock closing below the $1.00 minimum bid price for 32 consecutive business days, with a compliance period until January 14, 2026.
• The S-1 filing registers up to 40,000,000 shares for resale by Helena Global Investment Opportunities I Ltd. under an equity line of credit (ELOC) agreement, potentially providing Advanced Biomed with up to $25,000,000 in gross proceeds.
• The company will not receive any proceeds from the resale of shares by the selling stockholder, but will receive proceeds from the sale of shares to the selling stockholder under the ELOC agreement.
• As of March 31, 2025, the company reported a net loss of $2,557,358 for the nine-month period and $2,782,278 for the fiscal year ended June 30, 2024.
• Net cash used in operating activities was $4,281,093 for the nine-month period ended March 31, 2025, and $2,126,340 for the fiscal year ended June 30, 2024.
• The company's major stockholders and related parties waived off $2,820,624 in amounts due to them as of June 30, 2024, to improve working capital.
• The company completed an initial public offering on March 7, 2025, issuing 1,640,000 shares at $4.00 per share, generating $6.56 million in gross proceeds.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern due to significant working capital deficiency and net cash outflows from operating activities.

Sentiment

Score: 3

Explanation: The company is in a very early stage with no revenue, significant and continuous net losses, and negative operating cash flow, leading to a 'going concern' warning from its auditor. The Nasdaq delisting notice adds immediate pressure. While it has promising technology and a potential capital raise mechanism, the high operational and regulatory risks, coupled with the lack of commercialization, indicate a highly speculative and challenging outlook.

Positives

• Proprietary microfluidic technology platform enables rapid product development and improvement.
• Ultra-sensitive biosensor technology allows for fast and inexpensive early cancer diagnosis, with potential for cost reduction through mass production.
• A+Pre and AC-1000 devices and their corresponding chips have received NMPA clearance in China, indicating regulatory progress for core products.
• Pre-mass production trials for A+Pre Chips and AC-1000 Enrichment Chips demonstrated high performance, exceeding target recovery rates (94% vs 90% for A+Pre, 79.5% vs 75% for AC-1000) and blood cell depletion rates (>2.5 logs vs 2 logs).
• The A+LCGuard lung cancer early screening kit achieved 96% sensitivity and 99.9% specificity in a scientific research project involving 123 case studies.
• The company has a multi-disciplinary management team with expertise in semiconductor/integrated circuits and biomedical fields.
• Secured an equity line of credit agreement for up to $25,000,000, providing a potential source of future funding.
• Completed an initial public offering in March 2025, raising $6.56 million in gross proceeds.

Negatives

• The company is an early-stage cancer diagnostics company with a limited operating history and has not yet commenced product sales or generated any revenue.
• Expects to be in a state of continuous loss for the next two to three years.
• Incurred net losses of $2,557,358 for the nine-month period ended March 31, 2025, and $2,782,278 for the fiscal year ended June 30, 2024.
• Experienced significant net cash outflows from operating activities: $4,281,093 for the nine-month period ended March 31, 2025, and $2,126,340 for the fiscal year ended June 30, 2024.
• The auditor has expressed substantial doubt about the company's ability to continue as a going concern.
• Received a Nasdaq Deficiency Notice on July 18, 2025, for failing to meet the minimum $1.00 bid price requirement, risking delisting.
• The company has not conducted any clinical trials for its products as of the prospectus date, with A+LCGuard clinical research planned to start only by end of October 2025.
• Uncertainties and potential delays exist in obtaining regulatory approvals (NMPA, FDA, CE marking) for products in various jurisdictions.
• The company's products are not currently covered by China's National Medical Insurance Program, which may limit market adoption.
• Reliance on third parties for manufacturing and supply, which could lead to quantity, cost, or quality issues.
• Intellectual property protection is limited, and the company may face infringement claims or difficulties in enforcing its rights.
• The ELOC agreement can cause substantial dilution to existing shareholders as the purchase price fluctuates based on market price.
• The company's Shanghai subsidiary is subject to significant and rapidly changing Chinese government oversight and control, posing legal and operational risks.
• Geopolitical tensions between Taiwan and China could negatively affect business and investment value.

Risks

• Inability to develop or commercialize early cancer detection products on a timely basis or at all, due to lengthy and complex development processes, potential negative clinical trial results, or failure to obtain regulatory approvals.
• Failure to compete successfully with competitors who may have longer operating histories, larger customer bases, greater financial resources, or more advanced technologies.
• Products or services may not perform as expected, leading to inaccurate results, negative perception, and potential claims against the company.
• Vulnerability to natural disasters, health epidemics (like COVID-19), and civil/social disruption, which could significantly disrupt operations.
• Failure to attract and retain senior management and other key employees, including skilled scientists, technicians, and sales personnel.
• Difficulties in recruiting subjects for clinical trials, which could delay or adversely affect clinical development activities.
• Products may become obsolete if new products are not launched in a timely and cost-effective manner, impacting revenue and operations.
• Reliance on third parties for manufacturing, supply, and registration applications, increasing risks of insufficient quantities, unacceptable costs, or quality issues.
• Adverse effects from uncertainties and changes in China's regulations on the cancer screening industry, potentially leading to non-compliance or failure to obtain necessary approvals.
• Ongoing regulatory obligations and scrutiny, which may result in significant additional expenses, penalties, or withdrawal of marketing approvals if compliance is not maintained.
• Inability to obtain regulatory approval in North American or European markets, limiting geographic market expansion.
• Failure to obtain broad market acceptance or maintain a good reputation for current and future products, impacting sales and profitability.
• Uncertainty regarding coverage and favorable reimbursement rates from China's National Medical Insurance Program for products.
• Limited experience in product promotion and sales, posing risks to successful commercialization.
• Market size estimates for existing and future products may be lower than anticipated, adversely affecting sales growth.
• Security threats to information technology infrastructure and unauthorized use of data by third parties, potentially leading to liability or reputational damage.
• Inability to effectively protect intellectual property (patents, copyrights, trade secrets), leading to competitive harm or infringement claims.
• Exposure to litigation and other claims, which could result in substantial costs, diversion of management attention, and negative publicity.
• Incurrence of net losses and negative operating cash flows, raising substantial doubt about the ability to continue as a going concern and requiring additional capital.
• Raising additional capital may lead to dilution of existing stockholders' shareholdings and may impose restrictive covenants on operations.
• Risks associated with doing business in Taiwan, including restrictions on dividend payments, foreign exchange controls, and geopolitical tension with China.
• Risks associated with doing business in China, including rapid changes in government policies, potential intervention or influence over operations, and difficulties in enforcing foreign judgments.
• Potential delisting from Nasdaq Capital Market due to failure to meet listing requirements, including the minimum bid price requirement.
• Extreme stock price volatility and potential decline in share price, regardless of operating performance, especially given the relatively small public float.
• Future resales and/or issuances of common stock, including under the ELOC agreement, or the perception of such sales, may cause the market price to drop significantly.
• The company will not receive proceeds from the resale of shares by the selling stockholder, and actual proceeds from the ELOC may be less than the maximum amount.
• The company has broad discretion over the use of ELOC proceeds, which may not yield significant returns or align with investor expectations.
• The company's auditor, WWC, P.C., is headquartered in California and subject to PCAOB inspections, but if PCAOB is unable to inspect the auditor completely in the future, the company's securities may be delisted under the HFCAA.

Future Outlook

The company plans to initiate clinical research for its A+LCGuard lung cancer early screening kit by the end of October 2025, with completion anticipated within six months. This research will inform future large-scale clinical trials. The company also intends to expand into North American and European markets by establishing subsidiaries, aiming to complete US site selection and personnel recruitment by January 2026 and begin product registration, testing, and production. Localized registration of IVD products in Europe is also planned for 2026. The company anticipates being in a state of continuous loss for the next two to three years as it focuses on clinical development and regulatory approvals.

Management Comments

• "We are committed to the application research of integrating semiconductor technology and biotechnology."
• "We believe clinical research serves as the foundation for clinical trials, bridging the gap between preclinical studies and large-scale clinical trials."
• "We believe clinical trials enables an understanding of subject recruitment, facilitates the development of appropriate inclusion and exclusion criteria for later stages, and helps verify trial procedures."
• "We believe the results of the clinical research will inform the work plan for future large-scale clinical trials, minimizing waste from an excessively large sample size or insufficient statistical power due to a sample size that is too small."
• "We recognize that the clinical research results may differ from expectations and may not support our expected progression to clinical trials. If so, we plan to promptly optimize the product, adjust participant group selection, and modify the final protocol for large-scale clinical trials."
• "We expect to be in a state of continuous loss for the next two to three years."
• "We presently intend to retain all earnings to fund our operations and business expansions and have no plan to distribute earnings to stockholders."
• "We do not anticipate paying dividends or other distributions to our stockholders, including U.S. investors, in the foreseeable future."
• "We believe that enhancing and maintaining awareness of our trademarks and sglcell are critical to achieving widespread acceptance of our microfluidic biochip products, gaining trust for our testing devices and attracting customers."
• "We will strive to be a leading provider of precision oncology detection solutions."
• "We intend to initially focus on developing our cancer screening market in China and plan to expand our operations to other markets in the following years."
• "We aim to complete site selection and personnel recruitment in the United States in January 2026 and start product registration, testing and production afterward."
• "We plan to break into the European market in January 2026 and conduct localized management and operations in accordance with European regulations."
• "We also plan to begin the localized registration of our IVD products in Europe in 2026."
• "We believe our current practice complies with the Labor Contract Law and its amendments."
• "We believe that our existing cash $5,184,100 as of March 31, 2025 will be sufficient to meet our research and development and operating expenditures for a minimum period of approximately twelve months from the date of this prospectus."

Industry Context

The company operates in the early cancer detection market, specifically liquid biopsy, which is a rapidly growing segment. The global liquid biopsy market was valued at $8.94 billion in 2022 and is projected to reach $22.87 billion by 2030, indicating significant growth potential. The company's focus on physical mechanisms (antigen-independent) for CTC enrichment offers a potential advantage over traditional antibody-based methods, which are more expensive and may miss certain tumor cells. The industry is characterized by rapid technological changes and evolving standards, requiring continuous R&D and product upgrades. The company's strategy to initially focus on China, the world's most populous country with a high cancer incidence, aligns with a major market opportunity, with subsequent expansion plans for North America and Europe.

Comparison to Industry Standards

• Traditional antibody-labeling selection methods for CTC capture cost approximately $1,000 per chip and have processing times of up to 12 hours, and are highly dependent on antigen expression (e.g., EpCAM), potentially missing low-expression CTCs.
• The company's products use pure physical mechanisms (antigen-independent) to effectively enrich and detect CTCs with high or low antigen expressions and high viability, offering a potentially faster and more affordable method.
• The A+LCGuard Lung Cancer Early Screening Kit achieved 96% sensitivity and 99.9% specificity in a scientific research project, which compares favorably to Universal Diagnostics' liquid biopsy method for lung cancer (73% sensitivity, 90% specificity) and Beijing Akron Medical Technology Co., Ltd.'s Aifeiming gene methylation detection kit (86.83% clinical sensitivity).
• The AC-1000 device can achieve high throughput (800-1000 drops/s) and high flow rate (>0.7ml/hr) while completely removing red blood cells in peripheral blood samples within 30 minutes, and maintains a high recovery rate of 76-90% for targeted cells and leukocyte removal rate of >2.5 logs.
• The A+CellScan chip significantly reduces total detection time for immunostaining by 4-5 hours per sample compared to conventional methods, completing on-chip immunostaining in 30 minutes for one sample and batch processing for eight samples in 1.5 hours.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not aware of any pending or threatened material legal or administrative proceedings against it, and does not believe any claims exist that would have a material adverse effect on its financial position, operating results, or cash flows.

Related Party Transactions

• Dr. Hung To Pau, a former director and major stockholder, waived off $1,233,764 in initial public offering costs and certain expenditures due to him as of June 30, 2024.
• Well Fancy Development Ltd., a related corporation where Hung To Pau is a director and shareholder, waived off $1,586,860 in loans due to it as of June 30, 2024.
• Advanced Biomed Inc. (Taiwan) entered into an unsecured, interest-free loan with Dr. Yi Lu (Chairman and CEO) of approximately $107,810 in January 2023, with a balance of $107,810 as of March 31, 2025.
• Advanced Biomed Inc. (Taiwan) entered into multiple unsecured, interest-free loans with Well Fancy Development Ltd. totaling approximately $488,897 (NTD 16,226,488) as of March 31, 2025, for general working capital.
• Advanced Biomed Inc. entered into unsecured, interest-free loans to Well Fancy Development Ltd. totaling $274,975 as of March 31, 2025.
• Shanghai Sglcell Biotech Co., Ltd. entered into multiple unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. totaling approximately $764,810 (RMB5,550,000) as of March 31, 2025, for general working capital.
• Advanced Biomed Inc. (HK) entered into an unsecured, interest-free loan to Hung To Pau, Ph.D. amounting to $200,000 in July 2024.
• Shanghai Sglcell Biotech Co., Ltd. entered into three unsecured, interest-free loans to Hung To Pau, Ph.D. totaling approximately $44,131 (RMB320,247) between October and December 2024.
• The company issued 12,644,375 common shares to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang, and Qiang Chen on June 30, 2022, to settle debts totaling approximately $9.04 million (NTD 174,020,033 and RMB22,200,000).

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from the ELOC agreement, as the number of shares issued will vary with market price. Existing shareholders may experience a decline in share value due to future sales by the selling stockholder. The Nasdaq delisting threat poses a direct risk to liquidity and investment value. The company's 'going concern' issue indicates a high risk of capital loss.
• **Employees**: The company's financial instability and 'going concern' doubt could impact job security and future compensation. The company relies on attracting and retaining highly skilled R&D and sales personnel, which could be challenging given financial uncertainties.
• **Customers**: Potential customers may face uncertainty regarding product availability and long-term support due to the company's early stage and financial condition. Regulatory approval delays could impact product access.
• **Suppliers**: The company's liquidity issues and reliance on related party financing could pose risks to timely payments to suppliers, although related parties have waived some debts to improve working capital.
• **Creditors**: While some related party debts have been waived, the 'going concern' warning indicates a risk to creditors if the company cannot achieve profitability or secure sufficient additional funding.

Next Steps

• Initiate the trial stage of A+LCGuard clinical research by the end of October 2025, with anticipated completion within six months.
• Formulate a work plan for large-scale clinical trials for A+LCGuard based on clinical research results.
• Submit A+CellScan and A+CellScan Chips registrations to the NMPA (expected by December 2024).
• Complete preliminary works for A+SCDrop's registration application.
• Officially roll out the identification and counting service for circulating tumor cells once in-house developed staining reagents (A+CTCE, A+CTCM, A+EMT, A+CM) complete the NMPA registration process.
• Complete site selection and personnel recruitment in the United States by January 2026 for North America market expansion.
• Start product registration, testing, and production in the US after site selection and recruitment.
• Break into the European market in January 2026 and conduct localized management and operations.
• Begin localized registration of IVD products in Europe in 2026.
• Monitor the closing bid price of common stock and consider all available options to regain compliance with Nasdaq's Minimum Bid Price Requirement by January 14, 2026.
• Continue efforts to raise additional debt and equity financing to support operations and business expansion.

Key Dates

Recommendation

Advanced Biomed Inc. is a pre-revenue company with a history of significant and continuous net losses, coupled with substantial negative cash flow from operations. The auditor's 'going concern' warning highlights severe liquidity issues, indicating a high probability of financial distress without substantial additional funding. The recent Nasdaq Deficiency Notice for failing to meet the minimum bid price requirement adds immediate and critical delisting risk, which would severely impair liquidity and investor confidence. While the company has an ELOC agreement for potential capital, the proceeds are not guaranteed, and any issuance under it would cause significant dilution to existing shareholders. The company's products are still in various stages of regulatory approval and clinical trials, with no clear timeline for commercialization or revenue generation. Geopolitical risks associated with its operations in China and Taiwan further complicate the outlook. For a seasoned investor, the combination of pre-revenue status, persistent losses, going concern doubt, and imminent delisting risk makes this a highly speculative and unfavorable investment, warranting a strong sell recommendation.

Keywords

Cancer detection, Liquid biopsy, Microfluidic technology, Circulating tumor cells (CTCs), Oncology diagnostics, Medical devices, In-vitro diagnostics (IVD), NMPA clearance, Clinical trials, Biotechnology, Semiconductor technology, Equity line of credit (ELOC), Nasdaq listing, Going concern, China regulations, Taiwan operations, ADVB